NCT01376648

Brief Summary

Brown adipose tissue (BAT) is important in energy expenditure through thermogenesis although the regulatory factors are not well known in humans. There is evidence suggesting that the thyroid hormones affect BAT functions in lower mammals, but the effects of the thyroid hormones on BAT activity in humans are still unclear. The objective of this study was to investigate the effects of thyroid hormones on glucose metabolism of BAT and other organs in humans.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2009

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

June 17, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 20, 2011

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

June 20, 2011

Status Verified

November 1, 2009

Enrollment Period

2.4 years

First QC Date

June 17, 2011

Last Update Submit

June 17, 2011

Conditions

Hyperthyroidism

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Twenty Graves' disease-caused hyperthyroid patients who were newly diagnosed and untreated were included. All hyperthyroid patients were treated with Methimazole and had been followed up until their symptoms disappeared and the thyroid hormone levels went back to normal range.

You may qualify if:

  • Newly diagnosed and untreated hyperthyroid patients
  • Informed consent was obtained

You may not qualify if:

  • History of other endocrine diseases
  • Useing beta adrenergic blockade
  • Pregnant women
  • Pacemaker implantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huashan Hospital

Shanghai, 200040, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

TSH, TT3, TT4, fT3, fT4, γT3,Norepinephrine,Blood-fat,FPG,Insulin,Leptin,Aadiponectin,Retinol-binding protein 4,Fatty acid binding protein 4,IL-6,TNF-α,CRP,Monocyte chemotactic protein 1

MeSH Terms

Conditions

Hyperthyroidism

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Study Officials

  • Yiming Li, Dr.

    Huashan Hospital

    STUDY CHAIR

Central Study Contacts

Yiming Li, Dr.

CONTACT

862152888055yimingli@fudan.edu.cn

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 17, 2011

First Posted

June 20, 2011

Study Start

December 1, 2009

Primary Completion

May 1, 2012

Study Completion

May 1, 2012

Last Updated

June 20, 2011

Record last verified: 2009-11

Locations

CN(1)